Table 1.
Mutual exclusiveness of known synthetic lethal interactions
Synthetic lethal interactions | Mutually exclusive patterns shown in cancer genetic database | |
---|---|---|
Gene A | Gene B | |
BRCA1 | PARP1/PARP2 | Prostate Adenocarcinoma (TCGA, Provisional; N=499) |
ETS (ERG/ETV1) | PARP1 | Prostate Adenocarcinoma (TCGA, Provisional; N=499) |
PTEN | PLK4 | Prostate Adenocarcinoma (TCGA, Cell 2015; N=333) |
PTEN | PARP1 | Prostate Adenocarcinoma (TCGA, Cell 2015; N=333) |
KRAS | CDK1 | Pan-Lung Cancer (TCGA, Nat Genet 2016; N=1144) |
KRAS | PLK1 | Colorectal Adenocarcinoma (DFCI, Cell Reports 2016; N=619) |
MTAP | PRMT5 | Pan-Lung Cancer (TCGA, Nat Genet 2016; N=1144) |
VHL | EPAS1 (HIF2a) | Kidney Renal Clear Cell Carcinoma (TCGA, Provisional; N=538) |
ATM | PRKDC (DNAPK) | Skin Cutaneous Melanoma (TCGA, Provisional; N=419) |
MYC | BRD4 | Colorectal Adenocarcinoma (TCGA, Provisional; N=633) |
MYC | MTOR | Colorectal Adenocarcinoma (TCGA, Provisional; N=633) |
MYC | CDK1 | Prostate Adenocarcinoma (TCGA, Provisional; N=499) |